Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics

Journal of Controlled Release

Volumn 236, Issue , 2016, Pages 100-116

  Thompson, Pamela ^a   Fleming, Ryan ^a   Bezabeh, Binyam ^a   Huang, Fengying ^a   Mao, Shenlan ^a   Chen, Cui ^a   Harper, Jay ^a   Zhong, Haihong ^a   Gao, Xizhe ^a   Yu, Xiang Qing ^a   Hinrichs, Mary Jane ^a   Reed, Molly ^a   Kamal, Adeela ^a,b   Strout, Patrick ^a   Cho, Song ^a   Woods, Rob ^a   Hollingsworth, Robert E ^a   Dixit, Rakesh ^a   Wu, Herren ^a   Gao, Changshou ^a   Dimasi, Nazzareno ^a   more..

^a MEDIMMUNE   (United States)

^b Ferring Pharmaceuticals   (United States)

Author keywords

Antibody drug conjugates; Cysteine engineered antibodies; Fc gamma receptors; In vivo efficacy; Site specific conjugation; Tubulysin

Indexed keywords

AMINO ACIDS; COVALENT BONDS; DISEASES; MOLECULES; PHARMACOKINETICS;

ANTIBODY-DRUG CONJUGATES; FC-GAMMA RECEPTORS; IN-VIVO; SITE-SPECIFIC; TUBULYSIN;

ANTIBODIES;

ANTIBODY CONJUGATE; ANTIBODY TUBULYSIN CONJUGATE; CYSTEINE; CYTOTOXIC AGENT; FC RECEPTOR; IMMUNOGLOBULIN G; TUBULYSIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; DRUG CONJUGATION; DRUG DESIGN; DRUG EFFICACY; DRUG STABILITY; DRUG TARGETING; EX VIVO STUDY; FEMALE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MOUSE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; STEREOSPECIFICITY; ANIMAL; CELL SURVIVAL; CHEMISTRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOLECULARLY TARGETED THERAPY; NUDE MOUSE; PROTEIN STABILITY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYSTEINE; DRUG DESIGN; FEMALE; HUMANS; IMMUNOCONJUGATES; MICE, NUDE; MOLECULAR TARGETED THERAPY; PROTEIN STABILITY; RECEPTORS, FC;

EID: 84979071465     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.06.025     Document Type: Article

References (52)

1. [1] Imai, K., Takaoka, A., Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer 6 (2006), 714–727.
2. [2] Giaccone, G., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J. Clin. Oncol. 22 (2004), 777–784.
3. [3] Herbst, R.S., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J. Clin. Oncol. 22 (2004), 785–794.
4. [4] Rosell, R., et al. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). J. Clin. Oncol., 22, 2004, 618s.
5. [5] Thienelt, C.D., et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J. Clin. Oncol. 23 (2005), 8786–8793.
6. [6] Cunningham, D., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351 (2004), 337–345.
7. [7] Hurwitz, H., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350 (2004), 2335–2342.
8. [8] Huether, A., Hopfner, M., Baradari, V., Schuppan, D., Scherubl, H., EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem. Pharmacol. 70 (2005), 1568–1578.
9. [9] Huang, S., Armstrong, E.A., Benavente, S., Chinnaiyan, P., Harari, P.M., Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res. 64 (2004), 5355–5362.
10. [10] Xia, W., et al. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 24 (2005), 6213–6221.
11. [11] Matar, P., et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin. Cancer Res. 10 (2004), 6487–6501.
12. [12] Dienstmann, R., Markman, B., Tabernero, J., Application of monoclonal antibodies as cancer therapy in solid tumors. Curr. Clin. Pharmacol. 7 (2012), 137–145.
13. [13] Elloumi, J., Jellali, K., Jemel, I., Aifa, S., Monoclonal antibodies as cancer therapeutics. Recent Pat. Biotechnol. 6 (2012), 45–56.
14. [14] Boyiadzis, M., Foon, K.A., Approved monoclonal antibodies for cancer therapy. Expert. Opin. Biol. Ther. 8 (2008), 1151–1158.
15. [15] Rowland, G.F., O'Neil, G.J., Davies, D.A.L., Suppression of tumor growth in mice by a drug-antibody conjugate using a novel approach to linkage. Nature 255 (1975), 487–488.
16. [16] Dullens, H.F.J., De Weger, R.A., Oncostatic-antibody complexes in chemotherapy. Cancer Chemother. Pharmacol. 4 (1980), 29–32.
17. [17] Miller, J.L., FDA approves antibody-directed cytotoxic agent for acute myeloid leukemia. Am. J. Health Syst. Pharm. 57 (2000), 1202–1204.
18. [18] Bross, P.F., Beitz, J., Chen, G., Chen, X.H., Duffy, E., Kieffer, L., Roy, S., Sridhara, R., Rahman, A., Williams, G., Pazdur, R., Approval summary gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7 (2001), 1490–1496.
19. [19] Katz, J., Janik, J.E., Younes, A., Brentuximab vedotin (SGN-35). Clin. Cancer Res. 17 (2011), 6428–6436.
20. [20] Burris, H.A., Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Expert. Opin. Biol. Ther. 11 (2011), 807–819.
21. [21] McDonagh, C.F., Turcott, E., Westendorf, L., Webster, J.B., Alley, S.C., Kim, K., Andreyka, J., Stone, I., Hamblett, K.J., Francisco, J.A., Carter, P., Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng. Des. Sel. 7 (2006), 299–307.
22. [22] Junutula, J.R., Bhakta, S., Raab, H., Ervin, K.E., Eigenbrot, C., Vandlen, R., Scheller, R.H., Lowman, H.B., Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. J. Immunol. Methods 332 (2008), 41–52.
23. [23] Junutula, J.R., Raab, H., Clark, S., Bhakta, S., Leipold, D.D., Weir, S., Chen, Y., Simpson, M., Tsai, S.P., Dennis, M.S., Lu, Y., Meng, Y.G., Ng, C., Yang, J., Lee, C.C., Duenas, E., Gorrell, J., Katta, V., Kim, A., McDorman, K., Flagella, K., Venook, R., Ross, S., Spencer, S.D., Lee Wong, W., Lowman, H.B., Vandlen, R., Sliwkowski, M.X., Scheller, R.H., Polakis, P., Mallet, W., Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol. 8 (2008), 925–932.
24. [24] Junutula, J.R., Flagella, K.M., Graham, R.A., Parsons, K.L., Ha, E., Raab, H., Bhakta, S., Nguyen, T., Dugger, D.L., Li, G., Mai, E., Lewis Phillips, G.D., Hiraragi, H., Fuji, R.N., Tibbitts, J., Vandlen, R., Spencer, S.D., Scheller, R.H., Polakis, P., Sliwkowski, M.X., Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin. Cancer Res. 16 (2010), 4769–4778.
25. [25] Shen, B.Q., Xu, K., Liu, L., Raab, H., Bhakta, S., Kenrick, M., Parsons-Reponte, K.L., Tien, J., Yu, S.F., Mai, E., Li, D., Tibbitts, J., Baudys, J., Saad, O.M., Scales, S.J., McDonald, P.J., Hass, P.E., Eigenbrot, C., Nguyen, T., Solis, W.A., Fuji, R.N., Flagella, K.M., Patel, D., Spencer, S.D., Khawli, L.A., Ebens, A., Wong, W.L., Vandlen, R., Kaur, S., Sliwkowski, M.X., Scheller, R.H., Polakis, P., Junutula, J.R., Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat. Biotechnol. 30 (2012), 184–189.
26. [26] Hamblett, K.J., Senter, P.D., Chace, D.F., Sun, M.M.C., Lenox, J., Cerveny, C.G., Kissler, K.M., Bernhardt, S.X., Kopcha, A.K., Zabinski, R.G., Meyer, D.L., Francisco, J.A., Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 10 (2004), 7063–7070.
27. [27] Jackson, D., Gooya, J., Mao, S., Kinneer, K., Xu, L., Camara, M., Fazenbaker, C., Fleming, R., Swamynathan, S., Meyer, D., Senter, P.D., Gao, C., Wu, H., Kinch, M., Coats, S., Kiener, P.A., Tice, D.A., A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res. 68 (2008), 9367–9374.
28. [28] Dimasi, N., Gao, C., Fleming, R., Woods, R.M., Yao, X.T., Shirinian, L., Kiener, P.A., Wu, H., The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. J. Mol. Biol. 393 (2009), 672–692.
29. [29] Hogarth, P.M., Fc receptors: introduction. Immunol. Rev. 268 (2015), 1–5.
30. [30] Sondermann, P., Huber, R., Oosthuizen, V., Jacob, U., The 3.2 Å crystal structure of the human IgG1 Fc fragment-Fc gamma RIII complex. Nature 406 (2000), 267–273.
31. [31] Karnell, J.L., Dimasi, N., Karnell, F.G., Fleming, R., Kuta, E., Wilson, M., Wu, H., Gao, C., Herbst, R., Ettinger, R., CD19 and CD32b differentially regulate human B cell responsiveness. J. Immunol. 192 (2014), 1480–1490.
32. [32] Kung Sutherland, M.S., Walter, R.B., Jeffrey, S.C., Burke, P.J., Yu, C., Kostner, H., Stone, I., Ryan, M.C., Sussman, D., Lyon, R.P., Zeng, W., Harrington, K.H., Klussman, K., Westendorf, L., Meyer, D., Bernstein, I.D., Senter, P.D., Benjamin, D.R., Drachman, J.G., McEarchern, J.A., SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 122 (2013), 1455–1463.
33. [33] Jeffrey, S.C., Burke, P.J., Lyon, R.P., Meyer, D.W., Sussman, D., Anderson, M., Hunter, J.H., Leiske, C.I., Miyamoto, J.B., Nicholas, N.D., Okeley, N.M., Sanderson, R.J., Stone, I.J., Zeng, W., Gregson, S.J., Masterson, L., Tiberghien, A.C., Howard, P.W., Thurston, D.E., Law, C.L., Senter, P.D., A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjug. Chem. 24 (2013), 1256–1263.
34. [34] Uppal, H., Doudement, E., Mahapatra, K., Darbonne, W.C., Bumbaca, D., Shen, B.Q., Du, X., Saad, O., Bowles, K., Olsen, S., Lewis Phillips, G.D., Hartley, D., Sliwkowski, M.X., Girish, S., Dambach, D., Ramakrishnan, V., Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1). Clin. Cancer Res. 21 (2015), 123–133.
35. [35] Wang, S.Y., Weiner, G., Complement and cellular cytotoxicity in antibody therapy of cancer. Expert. Opin. Biol. Ther. 8 (2008), 759–768.
36. [36] Panowksi, S., Bhakta, S., Raab, H., Polakis, P., Junutula, J.R., Site-specific antibody drug conjugates for cancer therapy. MAbs 6 (2014), 34–45.
37. [37] Strop, P., Liu, S.H., Dorywalska, M., Delaria, K., Dushin, R.G., Tran, T.T., Ho, W.H., Farias, S., Casas, M.G., Abdiche, Y., Zhou, D., Chandrasekaran, R., Samain, C., Loo, C., Rossi, A., Rickert, M., Krimm, S., Wong, T., Chin, S.M., Yu, J., Dilley, J., Chaparro-Riggers, J., Filzen, G.F., O'Donnell, C.J., Wang, F., Myers, J.S., Pons, J., Shelton, D.L., Rajpal, A., Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem. Biol. 20 (2013), 161–167.
38. [38] Li, Y.J., Perry, S.R., Muniz-Medina, V., Wang, X., Wetzel, L.K., Rebelatto, M.C., Masson Hinrichs, M.J., Bezabeh, B.Z., Fleming, R.L., Dimasi, N., Feng, H., Toader, D., Yuan, A.Q., Xu, L., Lin, J., Gao, G., Wu, H., Dixit, D., Osbourn, J.K., Coats, S.R., A biparatopic HER2-targeting antibody-drug conjugate demonstrates potent anti-tumor activity in primary tumor models that are refractory to or ineligible for HER2-targeted therapies. Cancer Cell 29 (2016), 117–129.
39. [a] www.inteleos.com.
40. [b] www.clinicaltrials.gov.
41. [c] www.elsevierbi.com.
42. [d] www.clinicaltrials.gov/ct2/show/NCT00085709.
43. [e] www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm216458.htm.
44. [f] www.pfizer.com/files/news/press_releases/2010/mylotarg_discontinuation_062110.pdf.
45. [g] www.pfizer.com/files/products/mylotarg_hcp_letter.pdf.
46. [h] https://clinicaltrials.gov/ct2/show/NCT02576548?term=medi4276&rank=1.
47. [i] www.aaalac.org.
48. [j] http://appft.uspto.gov/netahtml/PTO/index.html.
49. [k] www.rcsb.org.
50. [l] www.ppdi.com/Services/Laboratories.aspx.
51. [m] www.pharsight.com/main.php.
52. [n] www.pymol.org.